The companies are targeting availability as soon as possible in 2018 and will continue to explore opportunities to help people better manage their diabetes.
The company will deliver its next generation product that includes both Dexcom CGM and Insulet's OmniPod pump data this summer.
Once launched, the system will be the first mobile-connected CGM in the EU and is indicated for adults and children as young as two years of age.
This is the first and only full mobile CGM system that allows adults and children as young as 2 years old to conveniently monitor and share glucose levels.
The two parties will develop a series of continuous glucose monitoring products that are designed to be smaller and less expensive than existing technologies.
The device uses secure wireless connection between a patient's receiver and mobile app to transmit glucose information to apps on the mobile devices.
With the new software, healthcare providers, patients and caregivers will now have glucose readings from a sensor that are closest yet to lab accuracy.
The remote mobile communications device used for Continuous Glucose Monitoring (CGM) has cleared the regulatory hurdle and is now ready to be sold in the U.S.
Dexcom mobile app is designed to aggregate glucose and other diabetes-related data from patients' devices and display the integrated data on a smartphone.